BIOASIS TECHNOLOGIES INC (BTI.CA) Stock Price, Forecast & Analysis
TSX-V:BTI • CA09064N1033
BTI.CA Key Statistics, Chart & Performance
The current stock price of BTI.CA is 0.005 CAD. In the past year, price decreased by -92.31%.
BTI.CA Technical Analysis
BTI.CA Financial Highlights
Over the last trailing twelve months BTI.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -163.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTI.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of -16.67% and a revenue growth 215.79% for BTI.CA
BTI.CA Ownership
BTI.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 596.271M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 380.328M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 141.303M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 69.23M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.875M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.45 | 30.481M | ||
| RVX | RESVERLOGIX CORP | N/A | 27.318M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.573M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About BTI.CA
Company Profile
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Burnaby, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). The company is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The firm is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
Company Info
BIOASIS TECHNOLOGIES INC
22420 Dewdney Trunk Road, Suite 300
Burnaby BRITISH COLUMBIA 06437 CA
CEO: Deborah Ann Rathjen
Employees: 0
Phone: 12035337082
BIOASIS TECHNOLOGIES INC / BTI.CA FAQ
What does BTI do?
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Burnaby, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). The company is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The firm is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
What is the stock price of BIOASIS TECHNOLOGIES INC today?
The current stock price of BTI.CA is 0.005 CAD.
Does BIOASIS TECHNOLOGIES INC pay dividends?
BTI.CA does not pay a dividend.
What is the ChartMill rating of BIOASIS TECHNOLOGIES INC stock?
BTI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of BIOASIS TECHNOLOGIES INC (BTI.CA) based on its PE ratio?
BIOASIS TECHNOLOGIES INC (BTI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
How many employees does BIOASIS TECHNOLOGIES INC have?
BIOASIS TECHNOLOGIES INC (BTI.CA) currently has 0 employees.
Can you provide the ownership details for BTI stock?
You can find the ownership structure of BIOASIS TECHNOLOGIES INC (BTI.CA) on the Ownership tab.